Zynex, Inc. Stock Plummets to New 52-Week Low of $1.05

Zynex, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 1.05 on November 6, 2025. This significant decline highlights the company's ongoing struggles, as it has experienced a staggering 88.91% drop in its stock price over the past year, contrasting sharply with the S&P 500's positive performance of 17.53% during the same period.
The company's financial metrics reveal a challenging landscape. Zynex has reported negative results for nine consecutive quarters, with a pre-tax profit of USD -11.12 million, reflecting a dramatic decline of 336.56%. Additionally, the operating cash flow has reached its lowest point at USD -7.19 million. The company's debt-to-equity ratio stands at 36.51, indicating a reliance on debt financing, while the return on equity is notably negative at -2,272.96%.

With a market capitalization of USD 46 million and a price-to-book ratio of 36.52, Zynex's stock performance continues to raise concerns among market observers, particularly given its consistent underperformance against the S&P 500 over the last three years.